An interventional study of Calcium Hydroxide (Ca(OH)2) Intracanal Medication and Calcium Hydroxide + Iodoform (Metapex) in Apical Periodontitis, sponsored by Medipol University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Medipol University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Periapical Periodontitis with a site in Turkey — 13 open to participants now, 20 under way, none of them phase 3. Periapical Periodontitis · Turkey.
Among the 81 studies in Periapical Periodontitis with a site in Turkey, this one is the 53rd largest by enrollment of the 75 interventional ones that give a count, is one of 10 that started in 2026, is one of 73 with no phase, and was the 57th registered.
281 studies on the registry are indexed under Periapical Periodontitis; 79 are open to participants now.
Browse Periapical Periodontitis studies →13 of the 81 studies in Periapical Periodontitis with a site in Turkey are open now. Recruiting first, the newest first:
Karadeniz Technical University · Sites in Turkey
Ages 18–65
Alanya Alaaddin Keykubat University · Sites in Turkey
Ages 18–70
Medipol University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Mustafa Kemal University · Sites in Turkey
Ages 18–60 · Healthy volunteers
ESRA DAĞCI · Sites in Turkey
Ages 18+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 43 Periapical Periodontitis studies recruiting now, 17 (40%) set no upper age limit and 25 (58%) stop at 75 or younger; 5 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
This study's enrollment of 45 is below the median of 60 across 246 interventional studies indexed under Periapical Periodontitis.
Median enrollment 66 across the 75 interventional studies, 60 across the 6 observational. Of the 60 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 81 have an industry lead sponsor. The 10 most frequent:
Medipol University is the lead sponsor of 328 studies on the registry; 86 are open to participants now.
Medipol University has 6 studies filed under Periapical Periodontitis — fewer than ten, so there is no comparison to draw.
7 of the studies in Periapical Periodontitis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07867314Recep Tayyip Erdogan UniversityEffect of Apical Patency on Periapical Lesion Healing | 2026-11-27 |
| NCT07850895Recep Tayyip Erdogan UniversityEffects of Irrigation Activation Methods on Periapical Healing in Chronic Apical Periodontitis | 2026-12 |
| NCT07921277Karadeniz Technical UniversityEffects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis | 2026-12-30 |
| NCT07714733Alanya Alaaddin Keykubat UniversityEffect of Different Apical Motion Algorithms on Postoperative Pain After Root Canal Treatment | 2027-03-15 |
| NCT07353008Mustafa Kemal UniversityEffect of Different Chelation Protocols on the Healing of Periapical Lesions in Teeth With Chronic Apical Periodontitis | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Periapical Periodontitis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Apical periodontitis is a chronic inflammatory disease caused by bacterial infection of the root canal system. Although mechanical cleaning and shaping reduce most microorganisms, bacteria may persist in areas that are difficult to reach, making the use of intracanal medicaments between treatment sessions clinically important.
Calcium hydroxide is one of the most commonly used intracanal medicaments because of its antibacterial properties. However, some resistant microorganisms, such as Enterococcus faecalis, may survive when calcium hydroxide is used alone. Therefore, combining calcium hydroxide with other agents, such as iodoform or corticosteroids, may improve its antibacterial effectiveness.
The purpose of this study is to compare the antibacterial activity of calcium hydroxide used alone or in combination with iodoform (Metapex) or betamethasone in patients with apical periodontitis. Bacterial load in root canals will be evaluated using droplet digital PCR (ddPCR), a highly sensitive molecular method that allows absolute quantification of bacteria. The results of this study are expected to provide evidence to support optimal intracanal medicament selection in endodontic retreatment cases.
Apical periodontitis is a chronic inflammatory condition of periapical tissues that develops as a result of persistent bacterial infection within the root canal system. While chemomechanical preparation significantly reduces the microbial load, bacteria may remain in anatomical complexities such as dentinal tubules, isthmuses, and apical ramifications. For this reason, intracanal medicaments are widely used between treatment sessions to enhance disinfection and improve treatment outcomes.
Calcium hydroxide is the most frequently used intracanal medicament due to its high pH and antibacterial properties. Nevertheless, certain microorganisms, particularly Enterococcus faecalis, have been shown to survive in alkaline environments, limiting the effectiveness of calcium hydroxide when used alone. To overcome this limitation, calcium hydroxide has been combined with various agents, including iodoform and corticosteroids, with the aim of enhancing antibacterial activity and reducing periapical inflammation.
Droplet digital PCR (ddPCR) is a novel molecular technique that enables absolute quantification of bacterial DNA without the need for standard curves and is less affected by PCR inhibitors compared to conventional quantitative PCR methods. Despite its advantages, the use of ddPCR in clinical endodontic research remains limited, particularly in in vivo studies evaluating intracanal medicaments.
This prospective, single-center clinical study aims to compare the antibacterial efficacy of three intracanal medicament protocols in patients with apical periodontitis undergoing endodontic retreatment: (1) calcium hydroxide alone, (2) calcium hydroxide combined with iodoform (Metapex), and (3) calcium hydroxide combined with betamethasone. Root canal samples will be collected at different treatment stages, and total bacterial load as well as Enterococcus faecalis levels will be quantified using ddPCR.
The findings of this study are expected to provide high-quality clinical evidence regarding the antibacterial effectiveness of commonly used intracanal medicaments and their combinations. The results may contribute to evidence-based decision-making in the selection of intracanal medicaments for the management of apical periodontitis, particularly in retreatment cases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive calcium hydroxide as an intracanal medicament as part of routine clinical care. The selection of the intracanal medicament is based on standard clinical decision-making and is not assigned by the study protocol.
Other: Calcium Hydroxide (Ca(OH)2) Intracanal Medication
This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive a combination of calcium hydroxide and iodoform (Metapex) as an intracanal medicament as part of routine clinical care. The intracanal medicament is selected according to standard clinical practice and is not assigned by the study protocol.
Other: Calcium Hydroxide + Iodoform (Metapex)
This cohort includes patients with apical periodontitis undergoing endodontic retreatment who receive a combination of calcium hydroxide and betamethasone as an intracanal medicament as part of routine clinical care. The choice of intracanal medicament is determined by routine clinical decision-making and is not assigned by the study protocol.
Other: Calcium Hydroxide + Betamethasone
In the Ch Groups CaOH was prepared and inserted into the canal by using lentülo spirals.
Mixture of CaOH and Iodoform was inserted into the canal by using lentulo spirals.
Mixture of CaOH and bethamethasone was inserted into the canal by using lentulo spirals.
Change in Total Bacterial Load in Root Canal Samples
The primary outcome is the change in total bacterial load in root canal samples collected during endodontic retreatment. Bacterial load will be quantified using droplet digital PCR (ddPCR) by measuring absolute bacterial DNA copy numbers at different treatment stages.
Time frame: From baseline to 7 days after intracanal medicament application
Change in Enterococcus faecalis Levels
This secondary outcome assesses the change in Enterococcus faecalis levels in root canal samples collected during endodontic retreatment. Enterococcus faecalis DNA will be quantified using droplet digital PCR (ddPCR) by measuring absolute DNA copy numbers before and after intracanal medicament application.
Time frame: From baseline to 7 days after intracanal medicament application
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Aug 2026, 7 months.
Of 172 non-industry interventional studies with no phase under Periapical Periodontitis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 7 months is below that.
Counting every sponsor, half of 173 studies reached it within 12 months; a quarter within 6 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Mar 2026 → Jan 2026, primary completion Nov 2026 → Aug 2026 and completion Mar 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.